These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 20687782)

  • 1. Overview perspective of bacterial resistance.
    Furtado GH; Nicolau DP
    Expert Opin Ther Pat; 2010 Oct; 20(10):1273-6. PubMed ID: 20687782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogens resistant to antibacterial agents.
    Chen LF; Chopra T; Kaye KS
    Infect Dis Clin North Am; 2009 Dec; 23(4):817-45, vii. PubMed ID: 19909886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment.
    McDonald LC
    Clin Infect Dis; 2006 Jan; 42 Suppl 2():S65-71. PubMed ID: 16355319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial pathogens (non-Mycobacterium) from sputum culture and antimicrobial susceptibility.
    Srifuengfung S; Sangsawang M; Komolpis P; Dhiraputra C; Chompanee B
    Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):96-9. PubMed ID: 9740278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003.
    Wu CJ; Lee HC; Lee NY; Shih HI; Ko NY; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2006 Apr; 39(2):135-43. PubMed ID: 16604246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The growing burden of antimicrobial resistance.
    Hawkey PM
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i1-9. PubMed ID: 18684701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial resistance in Europe and its potential impact on empirical therapy.
    Rossolini GM; Mantengoli E
    Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():2-8. PubMed ID: 19040461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiology of diabetic foot infections in a teaching hospital in Malaysia: a retrospective study of 194 cases.
    Raja NS
    J Microbiol Immunol Infect; 2007 Feb; 40(1):39-44. PubMed ID: 17332905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?
    Falagas ME; Bliziotis IA
    Int J Antimicrob Agents; 2007 Jun; 29(6):630-6. PubMed ID: 17306965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
    Garrison MW; Mutters R; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance patterns among selective Gram-negative bacilli from an intensive care unit in Trinidad, West Indies.
    Orrett FA
    Saudi Med J; 2004 Apr; 25(4):478-83. PubMed ID: 15083220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints.
    Papaparaskevas J; Tzouvelekis LS; Tsakris A; Pittaras TE; Legakis NJ;
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):187-94. PubMed ID: 19836184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of isolation and antimicrobial susceptibility of bacteria isolated from bloodstream infections at Children's Medical Center, Tehran, Iran, 1996-2000.
    Mamishi S; Pourakbari B; Ashtiani MH; Hashemi FB
    Int J Antimicrob Agents; 2005 Nov; 26(5):373-9. PubMed ID: 16213124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
    Roveta S; Marchese A; Debbia EA
    Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial drug resistance in Taiwan.
    Huang YT; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S174-8. PubMed ID: 19013350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.